5 research outputs found
Situs inversus totalis and secondary biliary cirrhosis: a case report
Situs inversus totalis is is a congenital anomaly associated with various visceral abnormalities, but there is no data about the relationship between secondary biliary cirrhosis and that condition. We here present a case of a 58 year-old female with situs inversus totalis who was admitted to our clinic with extrahepatic cholestasis. After excluding all potential causes of biliary cirrhosis, secondary biliary cirrhosis was diagnosed based on the patient's history, imaging techniques, clinical and laboratory findings, besides histolopathological findings. After treatment with tauroursodeoxycholic acid, all biochemical parameters, including total/direct bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and gama glutamyl transferase, returned to normal ranges at the second month of the treatment. We think that this is the first case in literature that may indicate the development of secondary biliary cirrhosis in a patient with situs inversus totalis. In conclusion, situs inversus should be considered as a rare cause of biliary cirrhosis in patients with situs inversus totalis which is presented with extrahepatic cholestasis
Assessment of the role of EGF +61A/G and EGFR R497K polymorphism in patients with inflammatory bowel disease: A case-control study
Aim: Epidermal growth factor (EGF) and epidermal growth factor
receptor (EGFR) play an important role in the regulation of cell growth,
survival, migration, apoptosis, proliferation, and differentiation. We aimed to
investigate the presence of EGF (+61A/G) and EGFR R497Kpolymorphisms in
patients with inflammatory bowel disease (IBD) and their associations with
clinical features of the patients.Methods: This case-control study included 91 IBD patients (45
Crohn’s disease (CD) patients and 46 ulcerative colitis (UC) patients) and 129
healthy controls (HC). EGF and EGFR were
genotyped by polymerase chain reaction
and restriction fragment length polymorphism techniques to elucidate their
association with clinical outcomes. The disease activity for UC and CD were
assessed by Truelove-Witts index (TW) and Crohn's disease activity index
(CDAI), respectively. The Montreal classification was used for disease
involvement and behavior.Results: EGFR497 AA genotype was significantly decreased in patients with
UC compared with CD and HC. In addition, the patients with UC who had EGF +61 A
allele had increased risk of moderate and severe disease (p=0.28; OR= 3.13; 95%
CI=0.34-28.73). The patients with CD who had the EGF61 AG genotype were
found to increased risk for the presence of penetrating disease (p=0.14; χ2=5.59; OR=5.00;
95% CI=1.26-19.83). EGF +61 A genotype carriers also had higher CDAI scores
(p=0.19; OR=4.00; 95% CI=0.44-36.14). In addition, A+ carriers were also found
to have higher requirement for anti-TNF treatment (p=0.11; OR=5.0; 95% CI=0.56-44.4).
Conclusion: In this study,
EGFR 497 AA genotype was found to decrease significantly in patients with UC
compared to HC and CD patients. To enlighten the mechanism, further studies with
larger sample groups are needed to clarify the role of the EGF (+61A/G) and
EGFR R497K genes polymorphism, and development of the etiology and pathogenesis
of IBD
Are adipocytokines inflammatory or metabolic mediators in patients with inflammatory bowel disease?
This study examined the adiponectin and leptin levels and insulin resistance (IR) in patients with inflammatory bowel disease (IBD) and the associations between these factors and IBD characteristics. Fasting serum leptin, adiponectin, glucose, and insulin levels, as well as inflammatory parameters, were measured in 105 patients with IBD (49 patients with Crohn's disease [CD], 56 patients with ulcerative colitis [UC]) and 98 healthy controls [HC]. IR was evaluated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Disease activity and severity in patients with UC were evaluated using the Truelove-Witts index, and patients with CD were evaluated using the Crohn's Disease Activity Index. Serum adiponectin levels were found to be significantly lower in patients with CD and UC (p < 0.001). Serum leptin levels were also found to be significantly higher in both the UC and CD groups (p < 0.001). When HOMA-IR levels were compared, no significant difference was detected for either the CD or UC groups compared with the controls. In conclusion, it was shown that leptin levels increased and adiponectin levels decreased in patients with IBD, which is thought to be related to chronic inflammation. The effects of adipocytokines in patients with IBD with inflammatory and metabolic processes need to be investigated in further broader studies